Fighting flu: novel CD8<sup>+</sup> T‐cell targets are required for future influenza vaccines
Samuel Liwei Leong, Stéphanie Gras, Emma J. Grant
Abstract
Abstract Seasonal influenza viruses continue to cause severe medical and financial complications annually. Although there are many licenced influenza vaccines, there are billions of cases of influenza infection every year, resulting in the death of over half a million individuals. Furthermore, these figures can rise in the event of a pandemic, as seen throughout history, like the 1918 Spanish influenza pandemic (50 million deaths) and the 1968 Hong Kong influenza pandemic (~4 million deaths). In this review, we have summarised many of the currently licenced influenza vaccines available across the world and current vaccines in clinical trials. We then briefly discuss the important role of CD8 + T cells during influenza infection and why future influenza vaccines should consider targeting CD8 + T cells. Finally, we assess the current landscape of known immunogenic CD8 + T‐cell epitopes and highlight the knowledge gaps required to be filled for the design of rational future influenza vaccines that incorporate CD8 + T cells.